Search clinical trials for: Dipeptidyl peptidase 4 (DPP 4) inhibitor

Total 2570 results

Ain Shams University

Completed

Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes

Diabetes Mellitus, Type 1 | NASH

Egypt
Changhua Christian Hospital

Completed

Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

Type 2 Diabetes Mellitus | Proteinuria
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Unknown

Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects

Vagotomy, Truncal

Denmark
Boehringer Ingelheim

Completed

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Diabetes Mellitus, Type 2

Saudi Arabia
Beni-Suef University
Faculty of Medicine, Minia University; Clinical Pharmacy Department, Faculty...

Not yet recruiting

The Effects of DPPIs on Cognitive Function of Diabetic Patients

Cognitive Impairment

Egypt
Mitsui Memorial Hospital
Mitsukoshi Health and Welfare Foundation

Completed

DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure

Heart Failure | Diabetes Mellitus

Japan
Boehringer Ingelheim

Completed

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Finland, Spain, Denmark, Germany, Israel, Japan, Norway, Sweden, Taiwan, United Kingdom
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes (SUSTAIN™)

Diabetes Mellitus, Type 2 | Diabetes

Japan
Brigham and Women's Hospital
Johns Hopkins University; National Institute on Aging (NIA); Rutgers University

Active, not recruiting

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Diabetes

United States
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetic Ketoacidosis | Lower Extremity Amputation | Urosepsis

Canada
Janssen Research & Development, LLC

Completed

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
University Hospital, Gentofte, Copenhagen
University of Copenhagen

Unknown

Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion

Liver Transplantation

Denmark
Takeda

Completed

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus (TRENDS)

Type 2 Diabetes

Japan
University of Pavia

Completed

Use of Incretins in Diabetic Patients

Diabetes Mellitus, Type 2

Italy
University of British Columbia

Terminated

Sitagliptin in Cystic Fibrosis-Related Diabetes

Cystic Fibrosis

Canada
Federal University of São Paulo
Novartis

Unknown

Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus

Type 1 Diabetes | Autoimmune Diabetes | Insulin Dependent Diabetes | Juvenile Onset Diabetes Mellitus

Brazil
LMC Diabetes & Endocrinology Ltd.
Merck Sharp & Dohme LLC; Syreon Corporation

Withdrawn

Approaches To Therapy Escalation In T2D (ATTACC)

Type2 Diabetes
Ajou University School of Medicine
Dong-A ST Co., Ltd.

Not yet recruiting

Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

Cerebral Infarction | Dipeptidyl-Peptidase IV Inhibitors | Infarction, Brain
Ain Shams University

Completed

Feasibility of DPP-4 Inhibitor Therapy on Advanced Hybrid Closed Loop System

Time in Range

Egypt
University of British Columbia
Merck Frosst Canada Ltd.

Completed

Sitagliptin in the Elderly

Type 2 Diabetes

Canada
Brigham and Women's Hospital

Completed

Replication of the CANVAS Diabetes Trial in Healthcare Claims

Diabetes

United States
University of Padova

Completed

Comparative Effectiveness of Dapagliflozin Versus DPP-4 Inhibitors (DARWIN-FUP)

Type 2 Diabetes

Italy
Brigham and Women's Hospital

Completed

Replication of the DECLARE Diabetes Trial in Healthcare Claims

Diabetes

United States
Brigham and Women's Hospital

Completed

Replication of the EMPAREG Diabetes Trial in Healthcare Claims

Diabetes

United States
Canadian Network for Observational Drug Effect...
Canadian Institutes of Health Research (CIHR); Drug Safety and Effectiveness...

Completed

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Myocardial Infarction | Heart Failure | Ischemic Stroke | Type2 Diabetes | Cardiovascular Death | All-Cause Mortality

Canada
Janssen Research & Development, LLC

Completed

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Attikon Hospital

Recruiting

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

Diabetes Type 2

Greece
Brigham and Women's Hospital

Completed

Replication of the LEADER Diabetes Trial in Healthcare Claims

Diabetes

United States
Sanofi

Completed

Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy (TED)

Diabetes Mellitus, Type 2

Korea, Republic of
Woman's
AstraZeneca

Completed

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis (BMS-AZPCOS)

Polycystic Ovary Syndrome | Disorder of Glucose Regulation

United States
Mayo Clinic
Patient-Centered Outcomes Research Institute

Active, not recruiting

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Type 2 Diabetes | Cardiac Disease

United States
dr. DJ Mulder
Boehringer Ingelheim

Completed

Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes (RELEASE)

Type 2 Diabetes Mellitus

Netherlands
Weill Medical College of Cornell University
Patient-Centered Outcomes Research Institute

Completed

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

Diabetes Mellitus, Type 2 | Renal Insufficiency, Chronic

United States
Emory University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Oral Anti Diabetic Agents in the Hospital

Diabetes Mellitus

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Diabetes Mellitus, Type 2

United Kingdom
Second Xiangya Hospital of Central South University
The First Affiliated Hospital with Nanjing Medical University; Beijing Hospital and other collaborators

Completed

Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Adult-onset Latent Autoimmune Diabetes

Diabetes Mellitus, Type 1

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Empa PASS on Urinary Tract Malignancies

Diabetes Mellitus, Type 2

Finland, Sweden, United Kingdom
Stanley Dudrick's Memorial Hospital

Terminated

The Use of DPP-4 Inhibitors in Short Bowel Syndrome (DPP-4)

Short Bowel Syndrome

Poland
Egymedicalpedia

Completed

Evaluation of the Effect of Self-Assembling Peptide P11-4

Dental Caries

Egypt
Boehringer Ingelheim
Eli Lilly and Company

Active, not recruiting

Comparative Effectiveness of Empagliflozin in the US

Diabetes Mellitus, Type 2

United States
Royal Devon and Exeter NHS Foundation Trust
King's College London; King's College Hospital NHS Trust; Newcastle University; Newcastle-upon-Tyne Hospitals NHS Trust and other collaborators

Completed

PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes (PROMASTER)

Diabetes

United Kingdom
Nestlé
Institut National de la Recherche Agronomique; Centre de Recherche en Nutrition...

Completed

Effects of Hesperidin on Bone Mineral Density and Bone Metabolism of Postmenopausal Women

Osteoporosis, Osteopenia

France
Jeffrey A. Cohen, MD
Jacobus Pharmaceutical

Terminated

Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS) (3-4DAP)

Muscle Weakness

United States
Chung-Ang University

Unknown

The Effect of DPP4 Inhibitor on Vasclular Healing

Diabetes Mellitus, Type 2 | Acute Coronary Syndrome

Korea, Republic of
Weill Medical College of Cornell University
National Institute on Aging (NIA)

Not yet recruiting

Living Memory Home-4-Dementia Care Pairs (LMH-4-DCP)

Dyadic Family Caregiver-person With Dementia Online Intervention

United States
GlaxoSmithKline

Completed

Glucagon-like Peptide (GLP) Utilization and Safety

Diabetes Mellitus, Type 2
University Hospital, Gentofte, Copenhagen

Completed

GA 6: The Blood Glucose-lowering Effect of Glucose-dependent Insulinotropic Polypeptide

Type2 Diabetes

Denmark
Boehringer Ingelheim

Completed

DIA_CENTRAL:T2D Treatment Pattern in Central Europe

Diabetes Mellitus, Type 2

Bulgaria, Czechia, Hungary, Poland, Russian Federation
Eli Lilly and Company

Completed

A Study Comparing Insulin Peglispro With Insulin Glargine as Basal Insulin Treatment

Type 2 Diabetes Mellitus

Japan, Taiwan, Korea, Republic of
The Catholic University of Korea

Completed

DPP4 Inhibitor and Coronary Atherosclerosis in Patients Receiving Insulin Therapy

Diabetes Mellitus

Korea, Republic of

Search clinical trials for: Dipeptidyl peptidase 4 (DPP 4) inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations